Bramah N. Singh | Academic Influence

Bramah N. Singh's AcademicInfluence.com Rankings

Bramah N. Singh

Computer Science

#10312

World Rank

#10821

Historical Rank

Computational Linguistics

#2600

World Rank

#2626

Historical Rank

Machine Learning

#4710

World Rank

#4763

Historical Rank

Artificial Intelligence

#5083

World Rank

#5149

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Bramah N. Singh's Degrees

PhD Computer Science Stanford University
Masters Computer Science Stanford University
Bachelors Computer Science University of California, Berkeley

Similar Degrees You Can Earn

Why Is Bramah N. Singh Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Bramah N. Singh was a cardiac pharmacologist and academic. Early life and education Born in Fiji, he graduated in medicine from University of Otago in 1963 and completed residency at Auckland Hospital, followed by a cardiology fellowship at Green Lane Hospital. In 1969, Singh was awarded a Nuffield travelling fellowship and moved to Oxford to work with Miles Vaughan Williams. There, he worked on the anti-arrhythmic properties of drugs including amiodarone. Such work helped to refine the characteristics of Class III compounds in the developing Vaughan Williams classification.

(See a Problem?)

Bramah N. Singh's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Rhythm control versus rate control for atrial fibrillation and heart failure. (2008) (1406)
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. (2007) (611)
Amiodarone versus sotalol for atrial fibrillation. (2005) (539)
Acute Hemodynamic and Clinical Effects of Levosimendan in Patients With Severe Heart Failure (2000) (476)
Primary structure of a human mitochondrial protein homologous to the bacterial and plant chaperonins and to the 65-kilodalton mycobacterial antigen (1989) (475)
Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia (1994) (374)
International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina (1998) (351)
Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation: a Veterans Affairs Cooperative Studies Program Substudy. (2006) (249)
A practical guide for clinicians who treat patients with amiodarone: 2007. (2007) (227)
Amiodarone compared with lidocaine for shock-resistant ventricular fibrillation (2002) (225)
Verapamil: A Review of its Pharmacological Properties and Therapeutic Use (1978) (178)
Cloning of Giardia lamblia heat shock protein HSP70 homologs: implications regarding origin of eukaryotic cells and of endoplasmic reticulum. (1994) (168)
Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction (1980) (166)
Proarrhythmia with Class III Antiarrhythmic Drugs: Definition, Electrophysiologic Mechanisms, Incidence, Predisposing Factors, and Clinical Implications (1995) (161)
Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: the Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. (2002) (148)
Cloning of the HSP70 gene from Halobacterium marismortui: relatedness of archaebacterial HSP70 to its eubacterial homologs and a model for the evolution of the HSP70 gene (1992) (130)
Mutagenic responses of thirteen anticancer drugs on mutation induction at multiple genetic loci and on sister chromatid exchanges in Chinese hamster ovary cells. (1983) (127)
Amiodarone kinetics after oral doses (1982) (122)
Chronic and Acute Effects of Dronedarone on the Action Potential of Rabbit Atrial Muscle Preparations: Comparison With Amiodarone (2002) (104)
Acebutolol: A Review of its Pharmacology, Pharmacokinetics, Clinical Uses, and Adverse Effects (1982) (90)
32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro. (1985) (89)
Current Antiarrhythmic Drugs (1999) (74)
Effects of Levosimendan on Cardiac Arrhythmia: Electrophysiologic and Ambulatory Electrocardiographic Findings in Phase II and Phase III Clinical Studies in Cardiac Failure (1999) (72)
Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. (2007) (72)
A pea chloroplast translation elongation factor that is regulated by abiotic factors. (2004) (70)
Kinetoplastid membrane protein-11 (KMP-11) is differentially expressed during the life cycle of African trypanosomes and is found in a wide variety of kinetoplastid parasites. (1995) (67)
Mitochondrial import of the human chaperonin (HSP60) protein. (1990) (66)
Amiodarone as Paradigm for Developing New Drugs for Atrial Fibrillation (2008) (65)
Effects of cardioselective beta adrenoceptor blockade on specific airways resistance in normal subjects and in patients with bronchial asthma (1976) (64)
Exercise capacity in atrial fibrillation: a substudy of the Sotalol-Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T). (2007) (59)
Amiodarone and Post‐MI Patients (1993) (58)
Maturation of 5-S rRNA: ribonuclease E cleavages and their dependence on precursor sequences. (1983) (57)
Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy (1997) (57)
Mutagenic responses of five independent genetic loci in CHO cells to a variety of mutagens. Development and characteristics of a mutagen screening system based on selection for multiple drug-resistant markers. (1982) (55)
Cloning and some novel characteristics of mitochondrial Hsp70 from Chinese hamster cells. (1997) (55)
Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. (1987) (54)
Nucleotide sequences and novel structural features of human and Chinese hamster hsp60 (chaperonin) gene families. (1990) (50)
Amiodarone: A multifaceted antiarrhythmic drug (2006) (48)
Autoantibodies to human heat shock protein (hsp)60 may be induced by Escherichia coli groEL (1996) (48)
The role of c-mos proto-oncoprotein in mammalian meiotic maturation. (1991) (47)
Control of rate versus rhythm in rheumatic atrial fibrillation: a randomized study. (2004) (45)
Morbidity and Mortality in Cardiovascular Disorders: Impact of Reduced Heart Rate (2001) (45)
Expression of human 60-kD heat shock protein (HSP60 or P1) in Escherichia coli and the development and characterization of corresponding monoclonal antibodies. (1992) (44)
Control of Heart Rate Versus Rhythm in Rheumatic Atrial Fibrillation: A Randomized Study (2004) (43)
Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). (2003) (43)
Antiarrhythmic and Proarrhythmic Properties of QT-Prolonging Antianginal Drugs (2004) (41)
Expanding Indications for the Use of Class III Agents in Patients at High Risk for Sudden Death (1995) (41)
Leishmania major: molecular cloning, sequencing, and expression of the heat shock protein 60 gene reveals unique carboxy terminal peptide sequences. (1997) (40)
Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. (2009) (39)
Congestive heart failure: Survival trial of antiarrhythmic therapy (CHF STAT) (1992) (38)
Requirement of the c-mos protein kinase for murine meiotic maturation. (1990) (38)
Cloning of HSP70 (dnaK) gene from Clostridium perfringens using a general polymerase chain reaction based approach. (1992) (36)
β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview (2005) (36)
Comparison of the mutagenic responses of 12 anticancer drugs at the hypoxanthine-guanine phosphoribosyl transferase and adenosine kinase loci in Chinese hamster ovary cells. (1983) (35)
Cloning of HSP60 (GroEL) operon from Clostridium perfringens using a polymerase chain reaction based approach. (1992) (33)
The development of monoclonal antibodies to the human mitochondrial 60-kd heat-shock protein, and their use in studying the expression of the protein in rheumatoid arthritis. (1992) (33)
Vimentin phosphorylation by p37mos protein kinase in vitro and generation of a 50-kDa cleavage product in v-mos-transformed cells. (1989) (33)
Cloning and characterization of cDNA for adenosine kinase from mammalian (Chinese hamster, mouse, human and rat) species. High frequency mutants of Chinese hamster ovary cells involve structural alterations in the gene. (1996) (32)
Electrophysiologic Effects of Ambasilide (LU 47110), a Novel Class III Antiarrhythmic Agent, on the Properties of Isolated Rabbit and Canine Cardiac Muscle (1992) (30)
Pharmacological Basis for the Therapeutic Applications of Slow-Channel Blocking Drugs (1982) (30)
Nucleotide sequences of three different isoforms of beta-tubulin cDNA from Chinese hamster ovary cells. (1991) (29)
Atrial Fibrillation: Epidemiologic Considerations and Rationale for Conversion and Maintenance of Sinus Rhythm (2003) (29)
Upstream therapies to prevent atrial fibrillation (2008) (29)
Metabolic Modulators for Chronic Cardiac Ischemia (2005) (28)
Efficacy and Safety of Sibutramine in Obese White and African American Patients With Hypertension (2000) (28)
The influence of inorganic phosphate on the activity of adenosine kinase. (2000) (28)
Characterization of MEK1 phosphorylation by the v-Mos protein. (1995) (28)
Comparative efficacy and safety of bepridil and diltiazem in chronic stable angina pectoris refractory to diltiazem (1991) (28)
Controlling Cardiac Arrhythmias by Lengthening Repolarization: Rationale from Experimental Findings and Clinical Considerations a (1992) (26)
Amiodarone Decreases Na,K-ATPase α2 and β2 Expression Specifically in Cardiac Ventricle (1994) (26)
Recognition of mos-related proteins with an antiserum to a peptide of the v-mos gene product. (1985) (26)
Species-specific differences in the toxicity and mutagenicity of the anticancer drugs mithramycin, chromomycin A3, and olivomycin. (1985) (25)
p37mos-associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos (1986) (25)
Control of Cardiac Arrhythmias by Calcium Antagonism a (1988) (24)
Mos and the cell cycle. (1997) (24)
Genomic Organization of the Mouse and Human Genes Encoding the ATP Sulfurylase/Adenosine 5′-Phosphosulfate Kinase Isoform SK2* (1999) (23)
Identification of the protein product of the c-mos proto-oncogene in mouse testes. (1988) (23)
Hypothyroidism Renders Protection Against Lethal Ventricular Arrhythmias in a Conscious Canine Model of Sudden Death (1991) (22)
Amiodarone-digoxin interaction during treatment of resistant cardiac arrhythmias (1982) (22)
Significance and Control of Cardiac Arrhythmias in Patients with Congestive Cardiac Failure (2002) (22)
Plasma timolol levels and systolic time intervals (1980) (21)
The effects of verapamil on coronary hemodynamics and vasomobility in patients with coronary artery disease (1980) (20)
The Clinical Results of Amiodarone in Cardiac Arrhythmias: Optimal Dosing (1984) (20)
Regulation of urokinase-type plasminogen activator expression by the v-mos oncogene. (1995) (20)
Cloning and characterization of a cell cycle-regulated gene encoding Topoisomerase I from Nicotiana tabacum that is inducible by light, low temperature and abscisic acid (2002) (20)
Mutagenic response to ultraviolet light and X-rays at five independent genetic loci in Chinese hamster ovary cells. (1982) (19)
Levosimendan and Calcium Sensitization of the Contractile Proteins in Cardiac Muscle: Impact on Heart Failure (2008) (19)
Induction of mutations at the thymidine kinase locus in CHO cells by restriction endonucleases. (1991) (17)
Cardiac Electrophysiologic Effects of Intravenous Ketanserin in Humans (1987) (17)
Structure-activity studies on mammalian adenosine kinase. (2000) (17)
Verapamil Hydrochloride: Pharmacological Properties and Role in Cardiovascular Therapeutics (1982) (17)
Moloney murine sarcoma virus encoded p37mos expressed in yeast has protein kinase activity. (1986) (17)
Rational Basis of Antiarrhythmic Therapy: Clinical Pharmacology of Commonly Used Antiarrhythmic Drugs (1978) (16)
Ribonuclease E is involved in the processing of 5-S rRNA from a number of rRNA transcription units. (1982) (16)
Phosphorylation of v-mos Ser 47 by the mitotic form of p34cdc2. (1991) (16)
Primary and secondary structure in a precursor of 5 S rRNA. (1982) (16)
The histidine-221 to tyrosine substitution in v-mos abolishes its biological function and its protein kinase activity. (1988) (16)
Inhibition of v-Mos kinase activity by protein kinase A (1996) (15)
Gene structure for adenosine kinase in Chinese hamster and human: high-frequency mutants of CHO cells involve deletions of several introns and exons. (2001) (15)
The physical interactions between p37env-mos and tubulin structures. (1992) (15)
Controlling cardiac arrhythmias: To delay conduction or to prolong refractoriness (1989) (15)
Mechanisms of Action of Antiarrhythmic Drugs Relative to the Origin and Perpetuation of Cardiac Arrhythmias (2001) (15)
Dose-Dependent Effects of Oral Dronedarone on the Circadian Variation of RR and QT Intervals in Healthy Subjects: Implications for Antiarrhythmic Actions (2006) (14)
The Electrophysiology and Pharmacology of Verapamil, Flecainide, and Amiodarone: Correlations with Clinical Effects and Antiarrhythmic Actions a (1984) (14)
Molecular characterization of a nuclear topoisomerase II from Nicotiana tabacum that functionally complements a temperature-sensitive topoisomerase II yeast mutant (2003) (14)
Antiarrhythmic and Arrhythmogenic Actions of Varying Levels of Extracellular Magnesium: Possible Cellular Basis for the Differences in the Efficacy of Magnesium and Lidocaine in Torsade de Pointes (1997) (14)
Quantitative mutagenesis at the adenosine kinase locus in Chinese hamster ovary cells. Development and characteristics of the selection system. (1983) (13)
Atrial fibrillation: from ion channels to bedside treatment options. (2009) (13)
Antiarrhythmic Actions of DL‐Sotalol in Ventricular and Supraventricular Arrhythmias (1992) (13)
Cell cycle-mediated structural and functional alteration of P85gag-mos protein kinase activity. (1990) (12)
Evidence for involvement of the protein kinase C pathway in the activation of p37v-mos protein kinase. (1990) (12)
Review : Sotalol: Current Status and Expanding Indications (1999) (12)
Mechanism of Action of Antiarrhythmic Agents: Focus on Propafenone (1987) (12)
Pharmacodynamic, Pharmacokinetic and Antiarrhythmic Properties of d-Sotalol, the Dextro-Isomer of Sotalol (1995) (12)
Sustained benefits of oral pentaerythritol tetranitrate on ventricular function in chronic congestive heart failure (1980) (12)
The P55 protein affected by v-mos expression is vimentin (1987) (11)
What niche will newer class III antiarrhythmic drugs occupy? (2001) (11)
THE EFFECTS OF PROPRANOLOL, PRACTOLOL AND METOPROLOL ON EXERCISE‐INDUCED TACHYCARDIA IN RELATION TO PLASMA LEVELS IN MAN (1976) (11)
Review : Restoring Sinus Rhythm in Patients with Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion? (1997) (10)
Further characterization of the c-mos transcript and its cell cycle specific expression in NIH3T3 cells. (1996) (10)
Azimilide Inhibits Multiple Cardiac Potassium Currents in Human Atrial Myocytes (2002) (10)
Hemodynamic effects of intravenous timolol in coronary artery disease (1979) (10)
Atrial Fibrillation Following Investigation of Rhythm Management: AFFIRM Trial Outcomes. What Might Be Their Implications for Arrhythmia Control? (2002) (10)
Oral verapamil vs propranolol in coronary artery disease: Evaluation of left ventricular function by exercise radionuclide ventriculography (1981) (10)
Newer antiarrhythmic agents for maintaining sinus rhythm in atrial fibrillation: simplicity or complexity? (2007) (10)
CIBIS, MERIT-HF, and COPERNICUS Trial Outcomes: Do They Complete the Chapter on -Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Drugs? (2001) (10)
PISA - A New Noninvasive Method for Early Detection and Quantification of Ischemia in Hypertensive Patients (1985) (10)
Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease (1999) (10)
Hemodynamic and electrocardiographic accompaniments of resting post-prandial angina (1978) (10)
A mycobacterial heat-shock protein-responsive gamma delta T cell clone also responds to the homologous human heat-shock protein: a possible link between infection and autoimmunity. (1991) (9)
Association of v-Mos with soluble vimentin in vitro and in transformed cells. (1993) (9)
Acute Management of Ventricular Arrhythmias: Role of Antiarrhythmic Agents (1997) (9)
Inhibition of c-mos protein kinase blocks mouse zygotes at the pronuclei stage. (1991) (9)
Chapter 100 – β-Blockers and Calcium Channel Blockers as Antiarrhythmic Drugs (2004) (9)
Enhanced mutability at the tk locus in the radiosensitive double-strand break repair mutant xrs5. (1990) (8)
4'-Demethylepipodophyllotoxin-beta-D-glucoside: a new podophyllotoxin derivative with VM-26-like and VP-16-213-like activities. (1984) (8)
Expression of the v-mos gene alters a Mr 55,000 protein during acute infection by Moloney murine sarcoma virus. (1986) (8)
Significance and Prevention of Atrial Fibrillation Occurring After Cardiac Surgery: A Time for Fundamental Change in Strategy? (1998) (8)
Use of antipeptide antibodies to probe the catalytic activity of p37v-mos. (1990) (8)
Clinical Implications of New Insights into Mechanism of Antiarrhythmic Drug Action (1992) (7)
Why a New Journal in Cardiovascular Pharmacology and Therapeutics? (1996) (7)
Cloning and expression of a nuclear encoded plastid specific 33 kDa ribonucleoprotein gene (33RNP) from pea that is light stimulated. (2001) (7)
Amiodarone and Homogeneity of Ventricular Repolarization and Refractoriness (1996) (7)
Electrophysiologic Effects of Flecainide Relative to Serum and Tissue Concentrations in Rabbits After Chronic Drug Administration (1989) (7)
Searching for the Ideal Class III Antiarrhythmic Agent: How Pure Should They Be? (1997) (6)
Reflections on Recent Clinical Trials in Patients With Heart Failure and Those With Reduced Ventricular Function (1997) (6)
Augmenting Maintenance of Sinus Rhythm in the Control of Atrial Fibrillation by Antiarrhythmic Drug Combinations (2010) (6)
Reviews: Pure Class III Antiarrhythmic Drugs: Focus on Dofetilide (2000) (6)
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. (2012) (6)
Hemodynamic Effects of Flestolol, a Titratable Short‐Acting Intravenous Beta‐Adrenergic Receptor Blocker (1988) (6)
A New Agent for Atrial Fibrillation: Electrophysiological Properties of Dronedarone (2010) (6)
Role of serum T4 and reversed T3 in monitoring antiarrhythmic efficacy and toxicity of amiodarone in resistant arrhythmias (1981) (6)
Hemodynamic and Electrophysiologic Effects of Combined Infusion of Lidocaine and Propafenone in Humans (1987) (6)
Review : Electrophysiologic and Antiarrhythmic Effects of Propafenone: Focus on Atrial Fibrillation (1999) (6)
Epicardial ST-segment reduction by vehapamil without change in experimental infarct size (1976) (6)
Newer Concepts in the Pathogenesis of Myocardial Ischaemia (1986) (5)
Editorial: Rise and Fall of Guided Antiarrhythmic Therapy for Ventricular Tachycardia and Fibrillation (1996) (5)
Antiarrhythmic Effects of Verapamil (1983) (5)
Effects of Hypoxia on the Cellular Electrical Activity of Adult and Neonatal Canine Ventricular Myocardium (1985) (5)
Acute Effects of Zatebradine on Cardiac Conduction and Repolarization (2002) (5)
Editorial note Intravenous calcium and verapamil — when the combination may be indicated (1983) (5)
Mechanism of action of a novel metabolically active antianginal agent (trimethazidine) delineated by PET (1996) (5)
Autoradiographic detection of diphtheria toxin resistant mutants in human diploid fibroblasts. (1985) (5)
Initial Antiarrhythmic Drug Therapy During Resuscitation from Sudden Cardiac Death: A Time for a Fundamental Change in Strategy? (2000) (5)
Amiodarone: Possibly an ideal antiarrhythmic agent (1982) (5)
v-mos proteins encoded by myeloproliferative sarcoma virus and its ts159 mutant (1992) (4)
Different Effects of Amiodarone and Quinidine on the Homogeneity of Myocardial Refractoriness in Patients With Intraventricular Conduction Delay (1998) (4)
Effects of Sotalol on the Circadian Rhythmicity of Heart Rate and QT Intervals With a Noninvasive Index of Reverse-Use Dependency (1999) (4)
Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm (2002) (4)
Arrhythmia Control by Selective Lengthening of Cardiac Repolarization: Role of N-Acetylprocainamide, Active Metabolite of Procainamide (1986) (4)
Ventricular Rate Control in Atrial Fibrillation: What is the Optimal Rate? The Concept of Controlling the Heart Rate Burden (2003) (4)
Inhibition of metabolic cooperation by phorbol esters in a cell culture system based on adenosine kinase deficient mutants of V79 cells. (1985) (4)
Temperature-dependent cytocidal effects of Moloney murine sarcoma virus. (1986) (4)
Electrophysiologic and Anti-Arrhythmic Effects of Sotalol in Patients with Life-Threatening Ventricular Tachyarrhythmias (1985) (3)
Recent advances in the management of atrial fibrillation (2008) (3)
Controlling Paroxysmal Atrial Fibrillation by a Combination of Amiodarone and Flecainide: Description of a Case With 15-Year Follow-up (1996) (3)
Class III Antiarrhythmic Drugs: Simple versus Complex Molecules for Controlling Cardiac Arrhythmias (1997) (3)
The electrophysiological properties of ranolazine: a metabolic anti-ischemic drug or an energy-efficient antiarrhythmic agent? (2011) (3)
Elevated level of cyclin D1 in mos-transformed cells. (1998) (3)
Amiodarone is more effective than placebo for spontaneous restoration and maintenance of sinus rhythm in patients with chronic artial fibrillation and congestive heart failure (1996) (3)
Differing effects of verapamil relative to varying levels of myocardial performance in patients with coronary artery disease (1981) (3)
Central Clinical Research Issues in Electrophysiology: Report of the NASPE Committee (2001) (3)
Clinical Electrophysiological Effects of Intravenous Recainam: An Antiarrhythmic Drug Under Investigation for the Treatment of Ventricular and Supraventricular Arrhythmias (1991) (2)
Calcium Antagonists (1983) (2)
β-Adrenoceptor Blocking Drugs and Acute Myocardial Infarction (1978) (2)
Pursuit of Sinus Rhythm in Patients with Atrial Fibrillation: Is the Effort Worth It? (2004) (2)
When is Drug Therapy Warranted to Prevent Sudden Cardiac Death? (2012) (2)
Evidence for interaction between v-Mos and a p34cdc2 isoform, p35cdk. (1992) (2)
Atrial Fibrillation: Defining Some Unanswered Questions (1998) (2)
Ischemic vs Non Ischemic Cardiomyopathy: Clinical Outcome and Response to Amiodarone (1996) (2)
Rate-Dependence of Antiarrhythmic Drug Action (2002) (2)
Oral N-acetylprocainamide compared to quinidine plus digoxin in the chronic suppression of atrial flutter in humans (1989) (2)
Reversion of thermosensitive splicing defect of Moloney murine sarcoma virus ts110 by oversplicing of viral RNA (1990) (2)
Antiarrhythmic Drugs in Cardiac Arrest Resuscitation: Intravenous Amiodarone or Intravenous Lidocaine? (2002) (2)
Abstract 3699: Dronedarone is Effective in Maintaining Sinus Rhythm in Atrial Fibrillation Patients in whom Previous Antiarrhythmic Drug Therapy has Failed (2006) (2)
Report of group IV: management options (1987) (2)
EFFICACY AND SAFETY OF BEPRIDIL IN CHRONIC STABLE ANGINA PECTORIS REFRACTORY TO NIFEDIPINE (1994) (2)
The Role of Calcium Antagonists in Acute Myocardial Infarction (1989) (2)
Introduction to “Changing Perspectives in Cardiac Arrhythmia Control: Agents, Techniques, Goals, and Outcomes” (1995) (1)
Chapter 37 – Antiarrhythmic Drugs (2005) (1)
Atrial Fibrillation: The Rate or Rhythm Controversy Can It be Resolved on the Basis of Clinical Trial Data? (2005) (1)
Adverse Effects of Amiodarone-Reply (1982) (1)
Levosimendan rapidly lowers plasma endothelin-1 and TNF-alpha levels in patients with severe heart failure (1999) (1)
Inhibition of viral mos gene-expression in transformed-cells restricts cell-cycle progression through g1-phase and g2-phase. (1992) (1)
Treatment of Atrial Fibrillation in 2010 and Beyond (2010) (1)
Acute effects of dronedarone on the potassium currents in human atrial cells (2002) (1)
707-5 Functional Correlates and Prognostic Importance of Chronic Atrial Fibrillation in Patients with Dilated Cardiomyopathy and CHF (1995) (1)
Prevalence and prognostic significance of silent myocardial ischemia in patients with unstable angina (1987) (1)
157 EFFECTS OF ACUTE HYPOXIA ON THE CELLULAR ELECTRICAL ACTIVITY OF NEONATAL AND ADULT PURKINJE FIBERS (PF) (1985) (1)
Amiodarone and Torsade de Pointes (1995) (1)
Prognostic Significance of Asymptomatic Ventricular Arrhythmias in Heart Failure: Potential for Mortality Reduction by Pharmacologic Control (1990) (1)
Hemodynamic Effects of N-Acetylprocainamide in Man: Comparison with other Antiarrhythmic Drugs (1986) (1)
32P-postlabeling (32P) analysis of DNA adduct formation with carcinogenic peroxisome proliferators (1985) (1)
Maintaining Sinus Rhythm in Atrial Fibrillation by Drug Therapy: Single Agents or Combinations? (2000) (1)
Frequent intragenic transcription termination within the N gene of vesicular stomatitis virus. (1982) (1)
Relationship between Amiodarone Efficacy and Serum Drug Levels in a Young Population (1986) (1)
Sudden Death During Flecainide Therapy for Atrial Fibrillation Complicating Wolff-Parkinson-White Syndrome (1996) (1)
IMPACT OF DRONEDARONE STARTED RAPIDLY AFTER AMIODARONE DISCONTINUATION (2010) (1)
Antiarrhythmic Therapy of Ventricular Arrhythmias: The Contemporary Dilemma (1996) (1)
Casses of Antianginal Compounds: Old and New—Therapeutic Implications (2003) (1)
Amiodarone abolishes circadian variability of QTc but not that of heart rate: Significance for prevention of sudden death (1991) (1)
A symposium : a new age in the pharmacologic therapy of cardiac arrhythmias (1996) (1)
798-6 Acute Effects of Zatebradine on Cardiac Conduction and Repolarization in Anesthetized Dogs (1995) (0)
Two-dimensional polyacrylamide gel electrophoretic analysis of [35S]methionine (35S-Met) labeled hepatocyte proteins reveals rapid induction of specific proteins by ciprofibrate, a peroxisome proliferator (1985) (0)
Influencing Mortality in Cardiac Disorders by Controlling Arrhythmias or by Cardioprotection: Whither Magnesium? (1996) (0)
Adrenergic receptors and their correlation with lengthening of cardiac repolarization by antiarrhythmic drugs (1986) (0)
Low-Cost Technique of Arsenic Removal from Groundwater with Underlying Mechanism (2013) (0)
Amiodarone Effects on Developing Myocardium (1986) (0)
Azimilide: A Viewpoint by Bramah Singh (2000) (0)
More on Amiodarone-Meeting the Challenges of the Combined Epidemics of Heart Failure and Atrial Fibrillation? (2003) (0)
Trisomy X (2020) (0)
EFFECTS OF ACUTE HYPOXIA ON CELLULAR ELECTRICAL PROPERTIES OF THE SINUS NODE (SN) AND ATRIUM (1984) (0)
PHARMACOLOGY OF BETA-ADRENERGIC BLOCKERS MECHANISM OF ACTION AND PHARMACOLOGICAL CLASSIFICATION OF 13-ADRENERGIC RECEPTOR BLOCKING DRUGS (2008) (0)
Comparative haemodynamic andperipheral vasodilator effects oforal andchewable isosorbide dinitrate inpatients withrefractory congestive cardiac (1979) (0)
1129-218 Ibutilide improves cardioversion success rates in patients on chronic amiodarone therapy with persistent atrial fibrillation (2004) (0)
Metabolism of amiodarone after chronic administration in the rabbit differs from that in man (1985) (0)
Specialty Conference Recent Trends intheManagement of Life-Threatening Ventricular Arrhythmias (1984) (0)
hythmicity of Rate-Normalized QT al in Hypothyroidism and Its nificance for Development of Class III tiarrhythmic Agents (1990) (0)
Reducing Perioperative Cardiac Risk in Noncardiac Surgery: A Time to Delineate Simpler Strategies? (2000) (0)
Cardiac electrophysiology and arrhythmias edited by charles fisch and boys surawicz elsevier science publishing co., inc., new york (199 1) 488 pages, illustrated, $84.00 isbn: 0-444-01601-5 (1993) (0)
A symposium : changing trends in antiarrhythmic therapy : worldwide experience with class III agents (1997) (0)
ELECTROPHYSIOLOGICAL (EP) EFFECTS OF D-SOTALOL ON HYPOXIG MYOCARDIUM (1984) (0)
Atrial Fibrillation: Emerging Possibilities for Drug Treatment: An Overview of Current Opportunities and Recent Developments (2003) (0)
Azimilide inhibits outward potassium currents in human atrial myocytes (2002) (0)
c,AnOfficial Journalof thecAmerican Heartc/Association, Inc. CURRENTTOPICS (1980) (0)
Pulmonary Effect of Amiodarone in Patients With Heart Failure fn1fn1This study was supported by the Department of Veterans Affairs Cooperative Studies Program of the Medical Research Service (Washington, D.C.), Sanofi Winthrop Recherche (Paris, France) and Wyeth-Ayerst Laboratories (Philadelphia, Pe (1997) (0)
P3-55: Effect of sotalol on mortality: A meta-analysis of randomized, placebo-controlled clinical trials (2006) (0)
82 EFFECT OF SOTALOL ON MORTALITY: A META-ANALYSIS OF RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIALS. (2007) (0)
Short‐Term Management of Ventricular Arrhythmias (1997) (0)
Discussion 1 : Pharmacology , Pharmacodynamics and Pharmacokinetics of Sotalol (1990) (0)
Quality of Life and Exercise Performance in Patients in Sinus Rhythm Versus Persistent Atrial Fibrillation A Cooperative Studies Program Substudy (2006) (0)
A NOVEL METABOLICALLY ACTIVE ANTIANGINAL AGENT (TRIMETHAZIDINE) ENHANCES PET MEASURED GLUCOSE UTILIZATION (1995) (0)
Antiarrhythmic Effects of Tricyclic Antidepressants-Reply (1982) (0)
Prolongation of Repolarization as Antifibrillatory Action Revisited: Drug Combination Therapy in Atrial Fibrillation (2005) (0)
The management of cardiac arrhythmias: The role of encainide and sotalol panel discussion Session 3: Class III activity: The utility of sotalol (1990) (0)
Calcium channel antagonism and beta blockade in combination—A therapeutic alternative in cardiovascular disorders. A review (1989) (0)
Increased InactiveCreatineKinaseB Proteinin the Plasmaof Patientswith Malignancy (2004) (0)
Concluding remarks: Cardiac arrhythmia (1985) (0)
Tinea (2005) (0)
The biological effects of antisense mos expression in fibroblasts. (1997) (0)
Alternating ST-Segment Deviation in Anterior and Inferior Elecfrocardiographic Leads during the Same Episode of Pain (2017) (0)
AMIODARONE AND TORSADE DE POINTES. AUTHORS' REPLY (1995) (0)
P26 03 WP – DNA DOUBLE-STRAND BREAKS AS MUTAGENIC LESIONS (1991) (0)
Survival Advantage with Cardiovascular Drugs: Are they Real? (2003) (0)
Calcium Antagonism in the Control of Cardiac Arrhythmias1 (1989) (0)
Antiarrhythmic actions of calcium antagonists (1994) (0)
TheEffect ofDelayinPropranolol Administration on Reduction ofMyocardial Infarct SizeAfter Experimental Coronary Artery Occlusion inDogs (1979) (0)
Arrhythmias: Technique ibsus k&Specific Responses in Evaluation of Efficacy (1993) (0)
Is Class III antiarrhythmic activity important? (1990) (0)
International Symposium on QT Prolongation and Ventricular Arrhythmias (1990) (0)
THE OFFICIAL BULLETIN OF THE INTERNATIONAL ACADEMY OF CARDIOVASCULAR SCIENCES (2003) (0)
Prevalence, Significance, and Control of Ventricular Arrhythmias in Patients with Heart Failure (1991) (0)
The Prevention of Sudden Cardiac Death Edited by John B. Kostis and Michael Sanders John Wiley & Sons, Inc., New York (1990) 316 pages, Illustrated, $69.50 ISBN: 0–471–56679–9 (1991) (0)
Somatic-cell expression of the mos protooncogene is cell-cycle regulated - highest RNA expression in the g2 phase. (1993) (0)
158 AMIODARONE (AM) ADVERSELY AFFECTS SINUS NODE (SN) FUNCTION IN VITRO (1985) (0)

This paper list is powered by the following services:

Other Resources About Bramah N. Singh

en.wikipedia.org

What Schools Are Affiliated With Bramah N. Singh?

Bramah N. Singh is affiliated with the following schools: